The Leeds Teaching Hospitals NHS Trust

Research and Innovation



This is a randomised controlled trial, looking at the effect of a number of tocilizumab has on those with severe Covid-19 pneumonia.   Tocilizumab is a biologic agent which has been used previously in the treatment of inflammatory arthritis.


This is a study which is considered a national priority.


Participants will be randomised into either tocilizumab or a placebo treatment

Who can participate?

Patients will be eligible if they are

  1. Adults (18 years +)
  2. Confirmation of SARS-CoV-2 infection by PCR
  3. SpO2 </= 93% or PaO2/FiO2 < 300 mmHg
  4. Agree to contraception or abstinence from sex for the duration of and 28 days after the final treatment